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by the only known cytoplasmic palmitoyl protein thio-
esterase APT1, an enzyme that has broad substrate
specificity but no global defect in ionomycin-treated T
cells. However, it seems likely that an accessory en-
zyme is upregulated in response to ionomycin treat-
ment that contributes to the selective inhibition of pal-
mitoylation and resultant hypophosphorylation of LAT.
This hypothesis is supported by the fact that LAT hypo-
phosphorylation is titratable with ionomycin and that
a small population of LAT in ionomycin-anergized T
cells does localize to the DRMs but is not phosphory-
lated. This unidentified LAT inhibitor could prevent
LAT palmitoylation by binding to the cysteine residues
or by facilitating the degradation of newly palmitoylated
LAT. E3 ligases can discriminate substrates based
upon complex posttranslational modifications such as
glycosylation or phosphorylation, and LAT has recently
been reported to be a target for ubiquitination (Brignatz
et al., 2005).
In conclusion, Hundt et al. (2006) have presented new
data suggesting in multiple model systems that defec-
tive LAT activation is associated with T cell anergy. Al-
though the exact mechanism for this inhibition is still
unclear, further work will no doubt clarify the role of
LAT in determining the balance between T cell activa-
tion or anergy induction.
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503Upstream toward the ‘‘DRiP’’-ing
Source of the MHC Class I Pathway
MHC class I binding peptides are generated via cyto-
solic degradation of a previously undefined substrate.
In this issue of Immunity, Kunisawa and Shastri (2006)
isolate pre-degradation polypeptide intermediates
bound to a cytosolic chaperone.
Around 150 years ago, intrepid explorers trekked
through the African hinterland to seek the elusive source
of the mighty Nile River. After many painful years of hack-
ing their way through previously unexplored jungle,
these explorers discovered a source of the river upon
which millions of African lives depend. In modern days
great wilderness adventurers are few and far between,
but within the cell, the search for the source of an intra-
cellular river of peptides, upon which millions of lives also
depend, is underway. In this case the ‘‘river’’ is the MHC
class I processing pathway, at the mouth of which pep-
tide-MHC class I complexes are presented on the sur-
face of the cell to CD8+ T cells. In this issue of Immunity,
Kunisawa and Shastri describe their trek upstream and
have made substantial progress toward the discovery
of a source of peptides in the MHC class I pathway.
Since the original discovery that 9–11 amino acid pep-
tides complexed to MHC class I were the substraterequired for CD8+ T cell activation (Townsend et al.,
1986), the source of these peptides has generated in-
tense investigation. Peptides complexed to MHC class
I can be generated from endogenous or exogenous pro-
tein sources in processes referred to as direct presenta-
tion or cross-presentation, respectively. Our focus here
will be the direct-presentation pathway, in which pep-
tides are generated from an endogenous antigen
source. Knowledge of the protein source of peptides
in the MHC class I pathway could eventually lead to
the development of vaccines that would allow more ef-
ficient generation of peptide-MHC class I complexes.
The increased numbers of peptide-MHC class I com-
plexes could then exceed the threshold required to trig-
ger low-affinity CD8+ T cells that are not tolerized during
exposure to substantial tumor burden or persistent viral
infection, providing a potential means of immunother-
apy. In addition to this therapeutic potential, two cell-bi-
ological observations revealed during ongoing investi-
gations of the MHC class I processing pathway have
intrigued researchers. The first observation was that it
was not possible to isolate or detect a peptide pre-
sented by a specific MHC class I molecule by biochem-
ical means unless the cells examined expressed that
MHC class I molecule (Falk et al., 1990). This could lead
to the conclusion that MHC class I molecules are ac-
tively involved in the generation of the peptides to which
they bind. However, Reits et al. demonstrated that cyto-
solic peptides have a very short half life (Reits et al.,
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504Figure 1. Sources of Endogenous Peptides in MHC Class I Presentation Pathway
MHC class I bound peptides can be derived from two distinct sources in the direct-presentation pathway. Intact protein can be translocated into
the endoplasmic reticulum, and peptides can be cleaved from lumenal termini of these proteins and then bind to newly synthesized MHC class I.
Folded intact proteins may also be degraded by the proteasome to produce peptides, although this process is inefficient. Alternatively misfolded
or truncated proteins may be rapidly degraded by the proteasome or TPPII. Prior to degradation, N- and C-terminally extended peptides asso-
ciate with Hsp90a. After degradation, N-terminally extended peptides associate with the chaperone TriC and are then transported into the ER via
TAP. Once in the ER, final trimming to the antigenic determinant occurs from the N terminus and is mediated by ERAAP. Peptide then binds to
MHC class I and transits to the cell surface. Shastri and colleagues have been instrumental in defining both post-degradation (1) and pre-deg-
radation (2) intermediates in this pathway.2003), and this may only be prolonged after sta-
bilization by either MHC class I molecules or molecular
chaperones. A second observation was that efficient
presentation of peptides derived from viral proteins
could be detected by CD8+ T cells rapidly after virus in-
fection. At the same time point after infection, however,
expression of the viral protein from which the peptideswere derived was barely detectable by biochemical
means, and total amounts of virus-derived protein con-
stituted only a minute fraction of the total pool of cellular
proteins (Esquivel et al., 1992). Thus, the amounts of an-
tigen within a cell are not always related to the amounts
of peptide-MHC complexes on the cell surface. Taken
together, these data lead to two conclusions. First, the
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cient presentation of foreign peptides; second, a purely
biochemical methodology is unlikely to approach the
exquisite sensitivity of naturally selected CD8+ T cells
when used to detect physiologically relevant concentra-
tions of peptides or peptide intermediates.
From the discovery that peptides bind to MHC class I,
researchers moved upstream toward the source of
these peptides by demonstrating that peptides bound
in the lumen of the endoplasmic reticulum (ER) and
reached this site primarily after transport via the hetero-
dimeric transporter of antigen processing (TAP). Before
transport to the ER, minimal peptide determinants that
bind to MHC class I are generated by the multicatalytic
proteasome and other cytosolic proteases, such as tri-
peptidyl peptidase. In addition, cytosolic proteases can
generate peptides that are extended at the N terminus
and more stable than smaller peptides; they can also
be transported into the ER by TAP and then further
cleaved to the minimal peptide prior to binding to
MHC class I. Although cytosolic cleavage could be
demonstrated, however, it was still not possible to iso-
late post-proteolytic peptides in the absence of the
MHC class I molecule to which they bind, indicating
a discontinuity in the trek upstream. In addition, a further
break in the trail stemmed from the inability to identify
proteins that were substrates for cytosolic cleavage,
and from which peptides could be generated rapidly in
the absence of protein accumulation.
A theory, therefore, was proposed that a rapidly de-
graded subset of proteins that do not accumulate intra-
cellularly was the major source of peptides in the MHC
class I pathway. These Defective Ribosomal Products
(DRiPs) are proteins targeted for degradation as a result
of premature termination or misfolding and could ac-
count for the generation of substantial quantities of
peptide-MHC complexes in the absence of detectable
accumulation of protein antigen (Yewdell et al., 1996).
Experimental evidence verified that DRiPs do exist
in vitro and in vivo (Schubert et al., 2000). Although in-
creased degradation, premature degradation, or mis-
folding can increase peptide presentation, there is cur-
rently no well-defined mechanistic link between the
generation of DRiPs and peptide-MHC class I complex
formation. Indeed, the insoluble characteristics of
DRiPs have precluded isolation of individual antigenic
species, indicating the inherent difficulties associated
with a purely biochemical approach.
In 1999, the Shastri laboratory developed the technol-
ogy to detect proteolytic substrates in the MHC class I
pathway. By altering the sequence of a model antigen,
chicken egg ovalbumin (OVA), to allow liberation of the
minimal antigenic peptide (SIINFEKL (Ova257–264)) from
longer polypeptides after cleavage by trypsin and car-
boxypeptidase B, they could use a sensitive T cell assay
to detect proteolytic intermediates (Paz et al., 1999). Ini-
tially, Kunisawa and Shastri utilized this approach to
isolate post-proteasomal N-terminally extended pep-
tides bound to the Group II chaperonin TRiC (Kunisawa
and Shastri, 2003). Although no direct linkage between
TRiC and TAP has been demonstrated, this observation
indicated that N-terminally extended peptides may be
protected from degradation in the cytosol to increase
the efficiency of presentation. In the current manuscript(Kunisawa & Shastri, 2006), they have now expanded
upon this work to isolate pre-proteasomal intermediates
that are extended from the minimal SIINFEKL determi-
nant at both the N and C termini. A substantial portion
of intermediates, which associated with the cytosolic
chaperone hsp90a, but not hsp90b, were degraded by
the proteasome; a greater variety of pre-proteasomal
intermediates were isolated after inhibition of proteaso-
mal function (Figure 1). In addition, inhibition of hsp90a
either with geldanamycin or via knockdown with interfer-
ing RNAs reduced antigen presentation to T cells. Finally,
the knockdown of the co-chaperone CHIP (carboxyl
terminus of Hsc70-interacting protein), a protein known
to complex with hsp90 and facilitate transfer of bound
substrates to the ubiquitin-proteasome-mediated deg-
radation pathway, also reduced antigen presentation.
Taken together, these observations move us further
toward the source of the MHC class I binding pathway.
However, they also raise a number of questions. Are the
pre-proteasomal intermediates found here DRiPs? Is
degradation required to generate these intermediates,
or are they premature truncation products? How preva-
lent is the requirement for association with hsp90a and
CHIP in MHC class I-mediated antigen presentation?
Molecular chaperones such as gp96 and hsp70 have
been touted as players in the MHC class I presentation
pathway, but primarily at the level of binding of protea-
somal products. The evidence that these chaperones
bind short peptides under physiological conditions, or
at relevant concentrations, is controversial. However,
the observation that antigen presentation in the pres-
ence of inhibitors of hsp90a and CHIP is reduced, but
not ablated, indicates that other chaperones may com-
pensate for the knockdown of these molecules.
The work of Kunisawa and Shastri has taken us fur-
ther up the river toward the source of peptide in the
MHC class I pathway, but has it taken us toward the only
source of peptide? SIINFEKL peptide can be presented,
albeit at a much reduced efficiency in comparison to en-
dogenously synthesized antigen, after the placement of
intact OVA into the cytosol of cells by electroporation or
osmotic lysis of pinosomes. Thus, under some circum-
stances, long-lived intact protein can be made available
to the MHC class I processing pathway, indicating that
a number of alternate antigen depots may exist for
use by the MHC class I pathway. Thus, although the
source of the MHC class I pathway may be close at
hand, it will be reassuring for intracellular explorers that
many tributaries of the peptide river remain to be ex-
plored in the future.
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Unraveling the Pros and Cons
of Interferon-g Gene Regulation
Although transforming growth factor-b (TGF-b) inhibi-
tion of interferon-g (IFN-g) expression has been
known for some time, in this issue of Immunity, Yu
et al. (2006) are the first to detail the crosstalk between
proinflammatory cytokine and TGF-b signaling that
regulates IFN-g expression.
The regulation of interferon-g (IFN-g) gene expression is
a complex process because multiple signals converge
to control both mRNA expression and posttranscrip-
tional protein expression. Whereas many different cell
types have been reported to express IFN-g, the most
important sources for IFN-g are T cells (both CD4+ and
CD8+), NKT cells, and NK cells. Regulation of IFN-g ex-
pression in T cells has been the subject of investigation
by many labs, but its expression in NK cells has been
less widely studied, in large part due to the difficulty in
transfecting these cells or infecting them with retroviral
or lentiviral vectors. Induction of IFN-g expression in NK
cells occurs through many different types of stimula-
tion, including cross-linking of cell-surface receptors
and stimulation with cytokines, including interleukin-2
(IL-2), IL-12, and IL-18. Different regulatory regions of
the IFN-g locus have been identified and numerous
transcription factors have been implicated in the activa-
tion of IFN-g transcription, thus making the understand-
ing of how this gene is transcriptionally regulated com-
plex, as the model is constantly changing.
Inhibition of IFN-g gene expression has been less
widely studied. It has been known for some time that
TGF-b inhibits IFN-g expression by NK cells (Bellone
et al., 1995; Hunter et al., 1995; Ye et al., 1995). Further-
more, a major phenotype resulting from the develop-
ment of TGF-b-deficient mice was massive overexpres-
sion of IFN-g (Shull et al., 1992). However, until now, the
molecular mechanisms by which TGF-b inhibits IFN-g
expression have not been elucidated.
As deciphered by Yu et al. in this issue of Immunity
(Yu et al., 2006), there is an important balance between
the cytokines IL-12 and IL-18, and TGF-b in NK cells.
When NK cells are treated with both IL-12 and IL-18,
a tremendous synergy with respect to IFN-g gene ex-
pression is observed (Okamura et al., 1998). A molecular
basis for this synergy is that IL-12 treatment leads to the
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strongly increased the recruitment of the IL-18-induced
transcription factor AP-1 to the IFN-g promoter (Naka-
hira et al., 2002). There is also reciprocal upregulation
of the receptors for both IL-12 and IL-18, thus making
the cells even more responsive to these stimuli. What
Yu et al. (2006) now show is that the IL-12 and IL-18
treatment also downregulates the ability of the NK cell
to respond to TGF-b (Figure 1). This process occurs
by both the downregulation of the mRNA and surface
expression of the TGF-b type II receptor (TGF-bRII) ex-
pression over time and the downregulation of SMAD2
mRNA. The SMAD family of transcription factors is crit-
ical for TGF-b signaling, so downregulation of these fac-
tors will decrease the cells’ ability to respond to TGF-b.
Additionally, SMAD3 protein, but not SMAD3 mRNA,
was also downregulated by the IL-12 and IL-18 treat-
ment. Of particular interest is the observation that the
overall downregulation of these signaling molecules
occurs under conditions of maximum IFN-g induction.
Although TGF-bRI and SMAD4 protein levels were not
affected, the inhibition of TGF-bRII and SMAD2 and
SMAD3 resulted in a decreased responsiveness to
TGF-b. Thus, as the cells are gearing up to maximally
produce IFN-g, their ability to respond to signals that
would dampen this response is weakened.
Next, theauthorsdirectlyexamined howTGF-b inhibits
IFN-gmRNA expression. They focused on two targets to
answer this question. The first target was T-bet, a gene
shown to be required for IFN-gexpression in CD4+ T cells
and NK cells (Szabo et al., 2002), and the second target
was the IFN-g gene itself (Figure 1). The authors clearly
demonstrate that there is a direct downregulation of
T-bet expression upon TGF-b treatment and that this
downregulation can be mediated through SMAD protein
interaction with the T-bet promoter (Figure 1). This effect
was maximized when SMAD3 and SMAD4 were used in
combination, whereas SMAD2 seemed to have little im-
pact on T-bet promoter activity. Interestingly, Yu et al.
(2006) could not overexpress SMAD4 in NK cells, and
although SMAD3 decreased T-bet in these cells, the ef-
fects were observed only in the presence of TGF-b, sug-
gesting that additional TGF-b-induced factors or protein
modifications (e.g., phosphorylation) are required. The
role of T-bet in IFN-g regulation has become controver-
sial, as a recent paper (Usui et al., 2006) showed that in
T cells, T-bet is not directly required for IFN-g expres-
sion. Instead T-bet was shown to inhibit GATA-3, a tran-
scription factor that inhibits IFN-g expression. However,
as shown in this manuscript, T-bet directly upregulates
activity of a truncated IFN-g promoter (2204), and
